EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 232 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... May 10, 2023 Keeping A Jasmine Plant In Your Room Reduces Anxiety, Panic Attacks... April 12, 2019 Can Having Solar Panels or Living Near a Solar Farm Increase... January 4, 2022 Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers February 19, 2025 Load more HOT NEWS 6 things you need to know about cervical screening Our 10 top tips to help you talk about cancer Addressing Cancer Pain with Complementary Methods (Part 2) Embracing Lung Cancer Survivorship
